Last updated: 23 February 2023 at 7:33pm EST

Michael McCormick Net Worth




The estimated Net Worth of Michael W Mc Cormick is at least $4.37 Millón dollars as of 22 October 2020. Mr. Cormick owns over 19,230 units of Perspective Therapeutics Inc stock worth over $15,832 and over the last 18 years he sold ISR stock worth over $4,353,095. In addition, he makes $0 as Independent Chairman of the Board at Perspective Therapeutics Inc.

Mr. McCormick ISR stock SEC Form 4 insiders trading

Michael has made over 21 trades of the Perspective Therapeutics Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he bought 19,230 units of ISR stock worth $10,000 on 22 October 2020.

The largest trade he's ever made was selling 82,727 units of Perspective Therapeutics Inc stock on 9 August 2012 worth over $4,353,095. On average, Michael trades about 3,711 units every 118 days since 2006. As of 22 October 2020 he still owns at least 41,230 units of Perspective Therapeutics Inc stock.

You can see the complete history of Mr. Cormick stock trades at the bottom of the page.





Michael McCormick biography

Michael W. McCormick serves as Independent Chairman of the Board of the Company. Mr. McCormick has been a Director of the Company since June 2015 and brings over 25 years of senior executive positions in global management, sales, and marketing to the Company. He was appointed Chairman of the Board effective as of June 4, 2018. He serves as a founder and partner of GO Intellectual Capital, which offers marketing services with a focus on the medical and aviation industries, as well as financial services. Previous to his service with GO, Mr. McCormick served as Executive Vice President of Global Sales and Marketing for Columbia Sportswear from 2006-2012, where his team successfully launched several new patented technologies, including Omni-Heat® Reflective and Omni-Freeze® Zero. During Mr. McCormick's tenure, Columbia built an intellectual property portfolio with over 200 patents. Mr. McCormick started his career with Nike, working in several senior management roles and ultimately becoming the Director of National Sales, U.S., prior to his departure in 1999. He also served as Chief Marketing Officer of Golf Galaxy from 2003-2006 and Executive Vice President of Global Sales and Marketing of Callaway Golf from 2000-2003. Mr. McCormick brings over 26 years of marketing experience in a diverse group of industries to his service on the Company's Board.



How old is Michael McCormick?

Michael McCormick is 55, he's been the Independent Chairman of the Board of Perspective Therapeutics Inc since 2018. There are 4 older and 11 younger executives at Perspective Therapeutics Inc. The oldest executive at Perspective Therapeutics Inc is Philip Vitale, 73, who is the Independent Director.

What's Michael McCormick's mailing address?

Michael's mailing address filed with the SEC is 5304 BRANDENBURG CT, , DALLAS, TX, 75287.

Insiders trading at Perspective Therapeutics Inc

Over the last 18 years, insiders at Perspective Therapeutics Inc have traded over $0 worth of Perspective Therapeutics Inc stock and bought 1,651,741 units worth $855,397 . The most active insiders traders include Lori A Woods, Thomas C Lavoy y Dwight William Babcock. On average, Perspective Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of $14,501. The most recent stock trade was executed by Lori A Woods on 13 April 2023, trading 187,500 units of ISR stock currently worth $114,375.



What does Perspective Therapeutics Inc do?

Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body.



What does Perspective Therapeutics Inc's logo look like?

Perspective Therapeutics Inc logo

Complete history of Mr. Cormick stock trades at Columbia Sportswear Co y Perspective Therapeutics Inc

Fecha
#
Empresa
Persona
Trans.
Transacción
Acciones Precio por acción Precio total Acciones después de Fuente
22 Oct 2020 Michael W Mc Cormick
Director
Comprar 19,230 $0.52 $10,000
22 Oct 2020
41,230
8 Mar 2016 Michael W Mc Cormick
Director
Comprar 22,000 $0.87 $19,140
8 Mar 2016
22,000
9 Aug 2012 Michael W Mc Cormick
VP/Sales
Venta 82,727 $52.62 $4,353,095
9 Aug 2012
2,978
29 Mar 2012 Michael W Mc Cormick
VP/Sales
Uso de opción 123 $23.66 $2,910
29 Mar 2012
23,435
5 Mar 2012 Michael W Mc Cormick
VP/Sales
Uso de opción 2,978 $24.57 $73,169
5 Mar 2012
23,312
20 Jan 2012 Michael W Mc Cormick
VP/Sales
Uso de opción 3,207 $23.18 $74,338
20 Jan 2012
20,756
29 Mar 2011 Michael W Mc Cormick
VP/Sales
Uso de opción 123 $28.71 $3,531
29 Mar 2011
18,716
1 Mar 2011 Michael W Mc Cormick
VP/Sales
Uso de opción 960 $30.74 $29,510
1 Mar 2011
18,593
21 Jan 2011 Michael W Mc Cormick
VP/Sales
Uso de opción 2,647 $29.78 $78,828
21 Jan 2011
18,055
1 Nov 2010 Michael W Mc Cormick
VP/Sales
Uso de opción 267 $26.07 $6,961
1 Nov 2010
16,255
10 May 2010 Michael W Mc Cormick
VP/Sales
Comprar 1,833 $54.00 $98,982
10 May 2010
15,988
2 Mar 2010 Michael W Mc Cormick
VP/Sales
Uso de opción 520 $23.23 $12,080
2 Mar 2010
14,155
21 Jan 2010 Michael W Mc Cormick
VP/Sales
Uso de opción 1,970 $20.62 $40,621
21 Jan 2010
14,131
2 Nov 2009 Michael W Mc Cormick
VP/Sales
Uso de opción 267 $18.93 $5,054
2 Nov 2009
12,572
27 Oct 2009 Michael W Mc Cormick
VP/Sales
Comprar 2,500 $40.00 $100,000
27 Oct 2009
12,305
7 Aug 2009 Michael W Mc Cormick
VP/Sales
Uso de opción 1,400 $18.08 $25,312
7 Aug 2009
10,302
27 Oct 2008 Michael W Mc Cormick
VP/Sales
Comprar 3,000 $33.00 $99,000
27 Oct 2008
8,902
7 Aug 2008 Michael W Mc Cormick
VP/Sales
Uso de opción 700 $19.40 $13,580
7 Aug 2008
6,151
9 May 2008 Michael W Mc Cormick
VP/Sales
Comprar 2,500 $41.32 $103,300
9 May 2008
5,451
5 Feb 2008 Michael W Mc Cormick
VP/Sales
Comprar 2,500 $40.73 $101,825
5 Feb 2008
2,951
7 Aug 2007 Michael W Mc Cormick
VP/Sales
Uso de opción 700 $30.26 $21,182
7 Aug 2007
700


Perspective Therapeutics Inc executives and stock owners

Perspective Therapeutics Inc executives and other stock owners filed with the SEC include: